Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00565539 · ClinicalTrials.gov registry record · Phase 1
Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection
A Phase 1 study of Hepatitis C, Chronic, sponsored by ZymoGenetics.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 11
- Study locations
NCT00565539: Completed Phase 1 study of Hepatitis C, Chronic, sponsored by ZymoGenetics.
NCT00565539 is a Phase 1 study of Hepatitis C, Chronic that has completed, run by ZymoGenetics. The registered enrollment target is 56 participants, below the 374-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (85% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00565539, a Phase 1 study of Hepatitis C, Chronic, has completed, sponsored by ZymoGenetics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 11
- Study locations
Study Summary
Interleukin 29 (IL-29) is a substance that is produced in the body to help fight viral infections. The purpose of this study is to test the safety and antiviral effects of PEG-rIL-29 (a man-made form of IL-29) when it is given either by itself at different doses or in combination with the approved dose of ribavirin (an antiviral drug) to subjects with hepatitis C infection who have received no prior treatment for this disease or who have relapsed following previous treatment with PEGylated interferon alpha (PEG-IFN-α), or other form of IFN-α, and ribavirin.
Conditions Studied
Interventions
- DRUG PEGylated recombinant interleukin 29 (PEG-rIL-29)
Study Locations (11)
Texas
- Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine - Houston
- St. Luke's Advanced Liver Therapies - Houston
- Alamo Medical Research - San Antonio
Illinois
- Northwestern Memorial Hospital - Chicago
Michigan
- Henry Ford Health System - Detroit
Minnesota
- Mayo Clinic - Rochester
New Jersey
- University Hospital (UMDNJ) - Newark
North Carolina
- Duke University Medical Center - Durham
Oregon
- Oregon Health Sciences University - Portland
Virginia
- VCUHS Hepatology Research Division - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
What the finished NCT00565539 record still lists
NCT00565539 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 374-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Hepatitis C, Chronic appearing as the primary indexed condition, and to 1 intervention - of which PEGylated recombinant interleukin 29 (PEG-rIL-29) is the first listed.
NCT00565539 lists 11 locations in 9 states (Texas, Illinois, Michigan).
Frequently Asked Questions
What is clinical trial NCT00565539 about?
NCT00565539 is a clinical study titled "Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection". Interleukin 29 (IL-29) is a substance that is produced in the body to help fight viral infections. The purpose of this study is to test the safety and antiviral effects of PEG-rIL-29 (a man-made form of IL-29) when it is given either by itself at different doses or in combination with the approved d...
What is the current status of trial NCT00565539?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2007-12. Estimated completion is 2009-10.
What conditions does trial NCT00565539 study?
This clinical trial studies the following conditions: Hepatitis C, Chronic.
What interventions are being tested in trial NCT00565539?
The interventions under investigation include: PEGylated recombinant interleukin 29 (PEG-rIL-29) (DRUG).
Who is sponsoring clinical trial NCT00565539?
This trial is sponsored by ZymoGenetics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00565539 being conducted?
This trial has 11 study locations across Illinois, Michigan, Minnesota, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00565539's enrollment target sits among peer trials
56 23rd of 26 higher than 4 of 26 other Hepatitis C, Chronic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C, Chronic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IdB 1016 Treatment for Hepatitis C Disease
COMPLETED · Phase 1
-
Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C
COMPLETED · Phase 1
-
Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced
COMPLETED · Phase 1
-
Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy
RECRUITING · Phase 4
-
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
ACTIVE NOT RECRUITING · Phase 4
-
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia